{{Drugbox
| Verifiedfields = 
| Watchedfields = 
| verifiedrevid = 
| IUPAC_name = [(8''R'',9''S'',13''S'',14''S'',17''S'')-17-hydroxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[''a'']phenanthren-3-yl] benzoate
| image = Estradiol benzoate.svg
| width = 250px

<!--Clinical data-->
| pronounce = {{IPAc-en|ˌ|ɛ|s|t|r|ə|ˈ|d|aɪ|oʊ|l|_|ˈ|b|ɛ|n|z|oʊ|eɪ|t}} {{respell|ES|trə|DYE|ohl|_|BEN|zoh|ayt}}
| tradename = Agofollin, Benovocyclin, Benzofoline, Dimenformon, Progynon-B, many others
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B            / C / D / X -->
| pregnancy_category = 
| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 -->
| legal_CA = 
| legal_UK = 
| legal_US = 
| legal_status = Rx-only
| routes_of_administration = [[Intramuscular injection]]

<!--Pharmacokinetic data-->
| bioavailability = {{font|size=95%|Intramuscular: 100%}}<small>{{Citation needed|date=October 2016}}</small>
| protein_bound = 
| metabolism = [[Bond cleavage|Cleavage]] via [[esterase]]s in the [[liver]], [[blood]], and [[tissue (biology)|tissue]]s<ref name="KuhnzBlode1993">{{cite journal|last1=Kuhnz|first1=W.|last2=Blode|first2=H.|last3=Zimmermann|first3=H.|title=Pharmacokinetics of Exogenous Natural and Synthetic Estrogens and Antiestrogens|volume=135 / 2|year=1993|pages=261–322|issn=0171-2004|doi=10.1007/978-3-642-60107-1_15}}</ref>
| metabolites = [[Estradiol]], [[benzoic acid]],<ref name="KuhnzBlode1993" /> and [[metabolite]]s of estradiol
| elimination_half-life = 
| duration_of_action = 4–5&nbsp;days (5&nbsp;mg {{abbr|i.m.|intramuscular}})<ref name="pmid7389356" />
| excretion = 

<!-- Identifiers -->
| CAS_number_Ref = 
| CAS_number = 50-50-0
| CAS_supplemental = 
| ATC_prefix = G03
| ATC_suffix = CA03
| ATC_supplemental = 
| PubChem = 222757
| IUPHAR_ligand = 
| DrugBank_Ref = 
| DrugBank = DBSALT000066
| ChemSpiderID_Ref = 
| ChemSpiderID = 193412
| UNII = 1S4CJB5ZGN
| KEGG = D01953
| ChEBI = 77006
| ChEMBL = 282575
| synonyms = Oestradiol benzoate; 17β-Estradiol-3-benzoate; NSC-9566; Benzhormovarine, Difollisterol, Follicormon, Follidimyl, Follidrinbensoat, Oestro-Vitis, Oestroform

<!--Chemical data-->
| C=25 | H=28 | O=3
| molecular_weight = 376.488 g/mol
| SMILES = O=C(Oc1cc3c(cc1)[C@H]2CC[C@@]4([C@@H](O)CC[C@H]4[C@@H]2CC3)C)c5ccccc5
| StdInChI_Ref = 
| StdInChI = 1S/C25H28O3/c1-25-14-13-20-19-10-8-18(28-24(27)16-5-3-2-4-6-16)15-17(19)7-9-21(20)22(25)11-12-23(25)26/h2-6,8,10,15,20-23,26H,7,9,11-14H2,1H3/t20-,21-,22+,23+,25+/m1/s1
| StdInChIKey_Ref = 
| StdInChIKey = UYIFTLBWAOGQBI-BZDYCCQFSA-N
}}

'''Estradiol benzoate''' ('''EB''', '''E2B'''), sold under the brand name '''Progynon-B''' among others, is an [[estrogen]] which is used in [[Europe]] and elsewhere throughout the world.<ref name="Elks2014">{{cite book|author=J. Elks|title=The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies|url=https://books.google.com/books?id=0vXTBwAAQBAJ&pg=PA897|date=14 November 2014|publisher=Springer|isbn=978-1-4757-2085-3|pages=897–}}</ref><ref name="Roberts1991">{{cite book | author = A. D. Roberts | title = Dictionary of Steroids: Chemical Data, Structures, and Bibliographies | url = https://books.google.com/books?id=qw5X0NK1A90C&pg=PA415 | accessdate = 20 May 2012 | year = 1991 | publisher = CRC Press | isbn = 978-0-412-27060-4 | page = 415}}</ref><ref name="IndexNominum2000">{{cite book | title = Index Nominum 2000: International Drug Directory | url = https://books.google.com/books?id=5GpcTQD_L2oC&pg=PA406 | year = 2000 | publisher = Taylor & Francis US | isbn = 978-3-88763-075-1 | page = 406}}</ref> It is a [[synthetic compound|synthetic]] [[estrogen ester]] which acts as a [[prodrug]] of [[estradiol]], and hence is considered to be a [[natural product|natural]] and [[bioidentical hormone replacement therapy|bioidentical]] form of estrogen.<ref name="KuhnzBlode1993">{{cite journal|last1=Kuhnz|first1=W.|last2=Blode|first2=H.|last3=Zimmermann|first3=H.|title=Pharmacokinetics of Exogenous Natural and Synthetic Estrogens and Antiestrogens|volume=135 / 2|year=1993|pages=261–322|issn=0171-2004|doi=10.1007/978-3-642-60107-1_15}}</ref> Estradiol benzoate was introduced in 1936 and was one of the first forms of estrogen to be marketed.<ref name="RaviñaKubinyi2011" /><ref name="pmid16746289" /> Along with [[estradiol dipropionate]], it was one of the most widely used estradiol esters prior to the 1950s.<ref name="pmid14388061" /> However, estradiol benzoate is now little used, having largely been superseded by longer-acting estradiol esters that require less frequent administration like [[estradiol valerate]] and [[estradiol cypionate]].<ref name="pmid7389356" />

{{TOC limit|3}}

==Medical uses==
{{Main|Estradiol (medication)#Medical uses}}

The [[medical use]]s of estradiol benzoate are the same as those of estradiol and other estrogens. An example of an indication for the drug is [[hormone replacement therapy]] for [[menopause|menopausal]] [[symptom]]s or [[hypoestrogenism]].

==Side effects==
{{Main|Estradiol (medication)#Adverse effects}}

The [[side effect]]s of estradiol benzoate are the same as those of estradiol. Examples of such side effects include [[breast tenderness]] and [[breast enlargement|enlargement]], [[nausea]], [[bloating]], [[edema]], [[headache]], and [[melasma]].<ref name="Ghosh2010">{{cite book|author=Amit K. Ghosh|title=Mayo Clinic Internal Medicine Board Review|url=https://books.google.com/books?id=LS65jBzoD40C&pg=PA222|date=23 September 2010|publisher=OUP USA|isbn=978-0-19-975569-1|pages=222–}}</ref>

==Pharmacology==

===Pharmacodynamics===
Esters of estradiol like estradiol benzoate are readily [[hydrolysis|hydrolyzed]] [[prodrug]]s of estradiol, but have an extended duration when administered in [[oil]] via [[intramuscular injection]] due to a [[depot injection|depot]] effect afforded by their [[fatty acid]] ester [[moiety (chemistry)|moiety]].<ref name="pmid16112947">{{cite journal | vauthors = Kuhl H | title = Pharmacology of estrogens and progestogens: influence of different routes of administration | journal = Climacteric | volume = 8 Suppl 1 | issue = | pages = 3–63 | year = 2005 | pmid = 16112947 | doi = 10.1080/13697130500148875 | url = }}</ref> As prodrugs of estradiol, estradiol benzoate and other estradiol esters are estrogens.<ref name="pmid16112947" />

===Pharmacokinetics===
Upon ingestion, regardless of the [[route of administration]], estradiol benzoate behaves as a [[prodrug]] via [[bond cleavage|cleavage]] by [[esterase]]s into estradiol and the natural [[fatty acid]] [[benzoic acid]].<ref name="pmid16112947" /> This cleavage occurs not only in the [[liver]], but also in the [[blood]] and in [[tissue (biology)|tissue]]s.<ref name="pmid16112947" /><ref name="KuhnzBlode1993" />

====Intramuscular administration====
{| class="wikitable floatright"
|+ Comparison of estradiol esters (5&nbsp;mg intramuscular)<ref name="pmid7389356">{{cite journal |vauthors=Oriowo MA, Landgren BM, Stenström B, Diczfalusy E | title = A comparison of the pharmacokinetic properties of three estradiol esters | journal = Contraception | volume = 21 | issue = 4 | pages = 415–24 |date=April 1980 | pmid = 7389356 | doi = 10.1016/s0010-7824(80)80018-7| url = }}</ref>
! Estrogen !! [[Cmax (pharmacology)|Peak levels]] !! [[Tmax (pharmacology)|Time to peak]] !! [[Pharmacodynamics#Duration of action|Duration]]
|-
| Estradiol benzoate || {{abbr|E2|Estradiol}}: 940&nbsp;pg/mL<br />{{abbr|E1|Estrone}}: 343&nbsp;pg/mL || {{abbr|E2|Estradiol}}: 1.8&nbsp;days<br />{{abbr|E1|Estrone}}: 2.4&nbsp;days || 4–5&nbsp;days
|-
| [[Estradiol cypionate]] || {{abbr|E2|Estradiol}}: 338&nbsp;pg/mL<br />{{abbr|E1|Estrone}}: 145&nbsp;pg/mL || {{abbr|E2|Estradiol}}: 3.9&nbsp;days<br />{{abbr|E1|Estrone}}: 5.1&nbsp;days || 11&nbsp;days
|-
| [[Estradiol valerate]] || {{abbr|E2|Estradiol}}: 667&nbsp;pg/mL<br />{{abbr|E1|Estrone}}: 324&nbsp;pg/mL || {{abbr|E2|Estradiol}}: 2.2&nbsp;days<br />{{abbr|E1|Estrone}}: 2.7&nbsp;days || 7–8&nbsp;days
|}

A single dose of 2.5&nbsp;mg estradiol benzoate by [[intramuscular injection]] was found to produce plasma estradiol levels of >400 pg/mL, measured 24 hours post-injection, in a group of patients with minimal baseline levels of estradiol (due to [[GnRH analogue]] therapy with [[triptorelin]]).<ref name="pmid8506068">{{vcite2 journal | vauthors = Vizziello G, D'Amato G, Trentadue R, Fanizza G | title = [Estradiol benzoate test in the study of pituitary block induced by triptorelin] | language = Italian | journal = Minerva Ginecol | volume = 45 | issue = 4 | pages = 185–9 | year = 1993 | pmid = 8506068 | doi = | url = }}</ref>

A single intramuscular injection of 5&nbsp;mg estradiol benzoate has been found to result in peak circulating concentrations of 940&nbsp;pg/mL estradiol and 343&nbsp;pg/mL estrone, which occurred at about 2 days post-injection (see table).<ref name="pmid7389356" /> Compared to two other commonly used estradiol esters (which were also assessed in the study), estradiol benzoate had the shortest duration, at approximately 4 to 5 days, whereas [[estradiol valerate]] and [[estradiol cypionate]] were found to last for 7–8 days and 11 days, respectively.<ref name="pmid7389356" /> This is because estradiol benzoate has a shorter and less bulky [[fatty acid]] [[side chain|chain]] and in relation to this is comparatively less [[lipophilicity|lipophilic]].<ref name="pmid16112947"/> For a given estradiol ester, the shorter or less extensive the fatty acid chain is, the less lipophilic, shorter-lasting, and less uniform/plateau-like the resultant levels of estradiol are as well as the higher the peak/maximal levels are (and hence more spike-like).<ref name="pmid16112947" />

==Chemistry==
{{See also|Estrogen ester}}

Estradiol benzoate is a [[synthetic compound|synthetic]] [[estrane]] (C18) [[steroid]] and the C3 [[benzoic acid|benzoate]] (or phenylcarboxylate) [[fatty acid]] [[ester]] of [[estradiol]].<ref name="Elks2014" /><ref name="Roberts1991" /><ref name="IndexNominum2000" /> It is also known as '''estra-1,3,5(10)-triene-3,17β-diol 3-benzoate'''.<ref name="Elks2014" /><ref name="Roberts1991" /><ref name="IndexNominum2000" /> Two related estradiol esters are [[estradiol dipropionate]], the 3,17β-dipropionate ester of estradiol, and [[estradiol acetate]], the 3-acetate ester of estradiol.

==History==
Estradiol benzoate was one of the first estrogens to be developed and marketed.<ref name="RaviñaKubinyi2011">{{cite book | author1 = Enrique Raviña | author2 = Hugo Kubinyi | title = The Evolution of Drug Discovery: From Traditional Medicines to Modern Drugs | url = https://books.google.com/books?id=iDNy0XxGqT8C&pg=PA175 | accessdate = 20 May 2012 | date = 16 May 2011 | publisher = John Wiley & Sons | isbn = 978-3-527-32669-3 | page = 175}}</ref><ref name="pmid16746289">{{cite journal | author = Folley SJ | title = The effect of oestrogenic hormones on lactation and on the phosphatase of the blood and milk of the lactating cow | journal = The Biochemical Journal | volume = 30 | issue = 12 | pages = 2262–72 |date=December 1936 | pmid = 16746289 | pmc = 1263335 | doi = | url = http://www.biochemj.org/bj/30/2262/bj302262.pdf}}</ref> In 1931, [[Adolf Butenandt]] found that the benzoic acid ester of estrone had a prolonged duration of action.<ref name="Labhart2012">{{cite book|author=A. Labhart|title=Clinical Endocrinology: Theory and Practice|url=https://books.google.com/books?id=DAgJCAAAQBAJ&pg=PA512|date=6 December 2012|publisher=Springer Science & Business Media|isbn=978-3-642-96158-8|pages=512–}}</ref><ref name="ButenandtHildebrandt1931">{{cite journal|last1=Butenandt|first1=A.|last2=Hildebrandt|first2=F.|title=Über ein zweites Hormonkrystallisat aus Schwangerenharn und seine physiologischen und chemischen Beziehungen zum krystallisierten Follikelhormon. [Untersuchungen über das weibliche Sexualhormon, 6. Mitteilung.]|journal=Hoppe-Seyler´s Zeitschrift für physiologische Chemie|volume=199|issue=4-6|year=1931|pages=243–265|issn=0018-4888|doi=10.1515/bchm2.1931.199.4-6.243}}</ref> Schwenk and Hildebrant discovered estradiol via [[redox|reduction]] of [[estrone]] in 1933, and they proceeded to [[chemical synthesis|synthesize]] estradiol benzoate from estradiol the same year.<ref name="OettelSchillinger2012">{{cite book|author1=Michael Oettel|author2=Ekkehard Schillinger|title=Estrogens and Antiestrogens I: Physiology and Mechanisms of Action of Estrogens and Antiestrogens|url=https://books.google.com/books?id=0BfrCAAAQBAJ&pg=PA8|date=6 December 2012|publisher=Springer Science & Business Media|isbn=978-3-642-58616-3|pages=8–}}</ref><ref name="pmid16746750">{{cite journal | vauthors = Miescher K, Scholz C, Tschopp E | title = The activation of female sex hormones: Mono-esters of alpha-oestradiol | journal = Biochem. J. | volume = 32 | issue = 8 | pages = 1273–80 | year = 1938 | pmid = 16746750 | pmc = 1264184 | doi = | url = }}</ref> Estradiol benzoate was patented by [[Schering-Kahlbaum]] in 1936 in an [[oil]] [[pharmaceutical preparation|preparation]] for [[Injection (medicine)|injectable]] use and was introduced later that year under the brand name Progynon-B.<ref name="RaviñaKubinyi2011" /><ref name="pmid16746289" /> Following its introduction, estradiol benzoate, along with [[estradiol dipropionate]], were the most widely used esters of estradiol for many years.<ref name="pmid14388061">{{cite journal | vauthors = SCHWARTZ MM, SOULE SD | title = Estradiol 17-beta-cyclopentylpropionate, a longacting estrogen | journal = Am. J. Obstet. Gynecol. | volume = 70 | issue = 1 | pages = 44–50 | year = 1955 | pmid = 14388061 | doi = | url = }}</ref> However, [[estradiol valerate]] and [[estradiol cypionate]], which are esters with improved [[pharmacokinetic]]s which require less frequent administration, were developed and introduced in the 1950s, and have since largely superseded estradiol benzoate in clinical practice.<ref name="pmid7389356">{{cite journal |vauthors=Oriowo MA, Landgren BM, Stenström B, Diczfalusy E | title = A comparison of the pharmacokinetic properties of three estradiol esters | journal = Contraception | volume = 21 | issue = 4 | pages = 415–24 |date=April 1980 | pmid = 7389356 | doi = 10.1016/s0010-7824(80)80018-7| url = }}</ref>

==Society and culture==

===Generic names===
''Estradiol benzoate'' is the [[generic term|generic name]] of the drug and its {{abbrlink|INN|International Nonproprietary Name}} while ''oestradiol benzoate'' is its {{abbrlink|BAN|British Approved Name}}.<ref name="Elks2014" /><ref name="Roberts1991" /><ref name="IndexNominum2000" />

===Availability===
Estradiol benzoate is not approved by the {{abbrlink|FDA|Food and Drug Administration}} for use in humans in the [[United States]].<ref name="Witherspoon1994">{{cite book|author=Richard Witherspoon|title=Presidents List of Articles Which May Be Designated Or Modified As Eligible Articles for Purposes of the U.S. Generalized System of Preferences|url=https://books.google.com/books?id=68n6f1Nw6EEC&pg=PA64|date=1 June 1994|publisher=DIANE Publishing|isbn=978-0-7881-1433-5|pages=64–}}</ref> However, it is approved and marketed in this country for [[veterinary use]] as a [[subdermal implant]] both alone and in combination with the [[anabolic-androgenic steroid]] [[trenbolone acetate]] (brand names '''Celerin''' and '''Synovex''', respectively).<ref name="Witherspoon1994" /><ref name="FDACelerinLabel">http://www.fda.gov/downloads/AnimalVeterinary/Products/ApprovedAnimalDrugProducts/FOIADrugSummaries/ucm116143.pdf</ref><ref name="FDASynovexLabel">http://www.fda.gov/downloads/AnimalVeterinary/Products/ApprovedAnimalDrugProducts/FOIADrugSummaries/UCM338208.pdf</ref>
==See also==
* [[High-dose estrogen]]
* [[List of estrogen esters]]

==References==
{{Reflist|30em}}


{{Estrogens and antiestrogens}}
{{Estrogen receptor modulators}}

[[Category:Alcohols]]
[[Category:Benzoates]]
[[Category:Estradiol esters]]
[[Category:Estranes]]
[[Category:Prodrugs]]
[[Category:Synthetic estrogens]]
[[Category:Veterinary drugs]]